According to Inhalation Sciences (ISAB), a US patent covering the XposeALI in vitro cell culturing module has been extended until 2034. US Patent No. 11054414 (“Exposure system”) was originally filed in 2013, the company said. The patent is now expected to expire in 2034.
The module, which works with the company’s PreciseInhale dry powder aerosol testing system, uses 3D epithelial cell models cultured in an air liquid interface and allows researchers to evaluate the effects of exposing lung cells to respirable aerosols. ISAB announced the XposeALI branding in 2015.
ISAB CEO Manoush Masarrat said, “The US is a major market with enormous potential. The outstanding capabilities and precision of XposeALI offers developers of inhaled pharmaceuticals in the US exceptional precision, reduced risk, and a major competitive advantage throughout coming decades.”
Read the Inhalation Sciences press release.
